Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 20;12(4):1675.
doi: 10.3390/jcm12041675.

Risankizumab Therapy for Moderate-to-Severe Psoriasis-A Multi-Center, Long-Term, Real-Life Study from Poland

Michał Adamczyk  1 , Joanna Bartosińska  1   2 , Dorota Raczkiewicz  3 , Kinga Adamska  4 , Zygmunt Adamski  4 , Maria Czubek  5 , Beata Kręcisz  6 , Elżbieta Kłujszo  6 , Aleksandra Lesiak  7 , Joanna Narbutt  7 , Marcin Noweta  7 , Agnieszka Owczarczyk-Saczonek  8 , Witold Owczarek  9 , Adam Reich  10 , Dominik Samotij  10 , Aleksandra Siekierko  7 , Justyna Szczęch  10 , Irena Walecka  11 , Piotr Ciechanowicz  11 , Anna Woźniacka  12 , Agata Liszewska  12 , Dorota Krasowska  1
Affiliations

Risankizumab Therapy for Moderate-to-Severe Psoriasis-A Multi-Center, Long-Term, Real-Life Study from Poland

Michał Adamczyk et al. J Clin Med. .

Abstract

The present multi-center, long-term, real-life study made an attempt to assess the efficacy of risankizumab in the treatment of moderate-to-severe plaque psoriasis. The study comprised 185 patients from 10 Polish dermatologic departments undergoing risankizumab treatment. The disease severity was measured using the Psoriasis Area and Severity Index (PASI) before the start of the risankizumab treatment and next at the defined timepoints, i.e., 4, 16, 28, 40, 52 and 96 weeks of treatment. The percentage of patients achieving PASI90 and PASI100 responses as well as the PASI percentage decrease at the defined timepoints were calculated, and correlations with clinical characteristics and therapeutic effect were analyzed. The number of patients evaluated at the defined timepoints was: 136, 145, 100, 93, 62, and 22 at 4, 16, 28, 40, 52 and 96 weeks of treatment, respectively. At 4, 16, 28, 40, 52 and 96 weeks, the PASI90 response was achieved in 13.2%, 81.4%, 87.0%, 86.0%, 88.7% and 81.8% of patients, whereas the PASI100 response was achieved in 2.9%, 53.1%, 67.0%, 68.8%, 71.0% and 68.2% of patients, respectively. Our study revealed a significant negative correlation between a decrease in the PASI and the presence of psoriatic arthritis as well as the patient's age and duration of psoriasis at several timepoints throughout the observation period.

Keywords: biologic treatment; psoriasis; real-life experience; risankizumab; systemic treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Changes in the PASI at weeks 4 (N = 136), 16 (N = 145), 28 (N = 100), 40 (N = 93), 52 (N = 62), 96 (N = 22). (a) PASI score in all study participants and (b) the mean PASI score with standard deviation (SD) during study timepoints. p < 0.001 for PASI at weeks 4, 16, 28, 40, 52 and 96 in all the comparisons to the baseline. p for Student’s t test for paired data.
Figure 2
Figure 2
The percentage decrease in PASI at weeks (a) 4 (N = 136), (b) 16 (N = 145), (c) 28 (N = 100), (d) 40 (N = 93), (e) 52 (N = 62) and (f) 96 (N = 22) compared to the baseline.
Figure 3
Figure 3
PASI90 and PASI100 at baseline (N = 185), weeks 4 (N = 136), 16 (N = 145), 28 (N = 100), 40 (N = 93), 52 (N = 62) and 96 (N = 22).
See this image and copyright information in PMC

References

    1. Armstrong A.W., Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA. 2020;323:1945–1960. doi: 10.1001/jama.2020.4006. - DOI - PubMed
    1. Elmets C.A., Leonardi C.L., Davis D.M.R., Gelfand J.M., Lichten J., Mehta N.N., Armstrong A.W., Connor C., Cordoro K.M., Elewski B.E., et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J. Am. Acad. Dermatol. 2019;80:1073–1113. doi: 10.1016/j.jaad.2018.11.058. - DOI - PubMed
    1. Blair H.A. Risankizumab: A Review in Moderate to Severe Plaque Psoriasis. Drugs. 2020;80:1235–1245. doi: 10.1007/s40265-020-01357-1. Erratum in Drugs 2020, 80, 1505. - DOI - PMC - PubMed
    1. Gordon K.B., Strober B., Lebwohl M., Augustin M., Blauvelt A., Poulin Y., Papp K.A., Sofen H., Puig L., Foley P., et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): Results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392:650–661. doi: 10.1016/S0140-6736(18)31713-6. - DOI - PubMed
    1. Papp K.A., Lebwohl M.G., Puig L., Ohtsuki M., Beissert S., Zeng J., Rubant S., Sinvhal R., Zhao Y., Soliman A.M., et al. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. Br. J. Dermatol. 2021;185:1135–1145. doi: 10.1111/bjd.20595. - DOI - PMC - PubMed

LinkOut - more resources